Stock events for REGENXBIO, Inc. (RGNX)
Over the past six months, REGENXBIO's stock has decreased by 10.92%. The company reported its fourth quarter and full-year 2025 financial results in March. The FDA issued a Complete Response Letter for RGX-121 in February. In January, the FDA placed clinical holds on the RGX-111 and RGX-121 programs after a tumor was identified in a participant, leading to a stock drop. Positive long-term data for RGX-202 in Duchenne muscular dystrophy was reported in January. Multiple securities class action lawsuits have been announced against REGENXBIO. As of March 7, 2026, the stock has a consensus rating of "Moderate Buy" with an average 12-month price objective of $27.70.
Demand Seasonality affecting REGENXBIO, Inc.’s stock price
Demand seasonality is not a significant factor for REGENXBIO, as demand for its investigational therapeutics is driven by clinical trial progress, regulatory milestones, and disease prevalence, rather than seasonal consumer patterns. Revenue is influenced by collaboration agreements, licensing, and royalty payments.
Overview of REGENXBIO, Inc.’s business
REGENXBIO Inc. is a clinical-stage biotechnology company focused on gene therapy, utilizing its NAV Technology Platform to develop and commercialize AAV gene therapies. Their pipeline includes ABBV-RGX-314 for retinal diseases, RGX-202 for Duchenne muscular dystrophy, RGX-121 for Mucopolysaccharidosis type II (Hunter syndrome), RGX-111 for Mucopolysaccharidosis type I, and RGX-181 and RGX-381 for late-infantile neuronal ceroid lipofuscinosis type II disease and ocular manifestations of CLN2 disease. REGENXBIO also licenses its NAV Technology Platform.
RGNX’s Geographic footprint
REGENXBIO Inc. is headquartered in Rockville, Maryland, United States, and primarily derives the majority of its revenue from the United States.
RGNX Corporate Image Assessment
REGENXBIO's brand reputation has been negatively impacted by regulatory setbacks, including clinical holds on RGX-111 and RGX-121 and a Complete Response Letter for RGX-121, leading to concerns about safety and regulatory pathways. These events have resulted in a stock price decline and securities class action lawsuits. The company highlights positive data for RGX-202 and anticipates key catalysts in 2026. The company maintains a "Moderate Buy" consensus rating from brokerages.
Ownership
REGENXBIO Inc. is predominantly owned by institutional shareholders (81.19%), with insiders holding 25.45% and retail investors holding 0.00%. Major institutional owners include BlackRock, Inc., Redmile Group, LLC, JPMorgan Chase & Co, Vanguard Group Inc, State Street Corp, Morgan Stanley, Goldman Sachs Group Inc, and Aqr Capital Management Llc. The largest individual insider shareholder is Allan M. Fox.
